Figure 11. Analysis of the expression of the transgene in the tumors developed in the K5-CYLDC/S mice and in their matched non tumoral tissue. Immunohistochemical staining with K5 and HA antibodies. (A, B) Snout sections from Control mice. K5 expression in the basal layer of the epidermis, HF and the immature cells of the sebaceous glands (A); HA is not detected (B). (C) HA expression in the snout of transgenic mice following the K5 expression pattern. HA expression in the tricofolliculoma of the snout (D) and in the SCC of the back skin of K5-CYLDC/S mice (E). (F-G) K5 expression in the basal layer of the epithelium of bronchia and bronchioles of Control mice (F); no HA staining was observed (G). (H, I) HA in bronchia and bronchioles of transgenic mice (H) and in alveolar cells (I). (J) HA expression in the lung ADC. (K, L) K5 expression in the myoepithelial cells around the mammary secretory acini of Control mice (K); HA is not detected (L). (M) HA in the mammary secretory acini of lactating transgenic mice following the K5 expression patter. (N) HA expression in the mammary adenomyoepithelioma. (O, P) Stomach from a Control mice showing K5 expression in the aglandular epithelia (forestomach, fs), plica (pl), and in scattered glands (g) (O); HA is not expressed (P). (Q) Expression of HA in the stomach of transgenic mice following the K5 expression pattern. (R) Gastric carcinoma in situ expressing HA. (S, T) Neither K5 nor HA are expressed in the liver of Control mice. (U) HA is not detected in hepatocytes of K5-CYLDC/S mice. (V) HA is not expressed in the hepatocarcinomas (HCC) of transgenic animals. Scale bars: 300 μm (A-C; N, R); 150 μm (D, E, I, J); 70 μm (K-M); 250 μm (G, O, P); 200 μm (F, H, Q, V); 100 μm (S-U). ADC: adenocarcinoma.